Observational Study of Prophylaxis and Treatment of Acute Perioperative Bleeding With Beriplex® P/N (Probe Study)

Inclusion Criteria (All): For all cohorts: •≥ 16 years of age * Received treatment with: * Beriplex® P/N * or FFP and Beriplex® P/N (in subsequent order) * or FFP only * INR and/or PT results available in connection with administration of Beriplex® P/N or FFP: * within 3 hours directly before and after administration of Beriplex® P/N or FFP In case of Beriplex® P/N use subsequent to FFP, additional results of INR and PT between the administration of the two products Cohort P (Prophylaxis Group): * Chronic liver disease, acute liver failure, or other conditions requiring correction of coagulopathy * Coagulopathy (INR \> 1.4 and/or PT ≥ 3 sec of upper limit of normal \[ULN\]) * Any planned major or minimally invasive procedure, except liver transplantation Cohort T (Treatment Group): * Acute perioperative bleeding (as assessed by the investigator) Exclusion Criteria: * Treatment with prothrombin complex concentrates (PCCs) other than Beriplex® P/N * Acquired deficiency of the vitamin K-dependent coagulation factors (e.g., as induced by treatment with oral vitamin K antagonists)